| A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants (NCT07716241) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-09-22 |
| Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC (NCT07754123) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-09-17 |
| A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia (NCT07759869) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-09-09 |
| A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis (NCT07765628) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-08-06 |
| A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504 (NCT07770217) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-08-02 |
| A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504 (NCT07764692) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Mass Balance Study of [14C]HS-10504 (NCT07764705) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-07-30 |
| Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors. (NCT07615413) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-30 |
| An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer (NCT07685041) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-27 |
| A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder (NCT07677384) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-12 |
| A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy (NCT07468851) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-10 |
| A Study of HS-10587 in Patients With Advanced Solid Tumors (NCT07567859) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-04 |
| A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension (NCT07609875) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-06-01 |
| A Study of HS-10506 in Chinese Patients With Insomnia Disorder (NCT07587385) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-05-29 |
| A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease (NCT07555054) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-05-21 |
| A Study of HS-20136-2 in Healthy Participants (NCT07483437) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-05-15 |
| A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants (NCT07535970) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-04-30 |
| Phase 1 Study of HS-20152 in Healthy Participants (NCT07503015) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-04-22 |
| A Phase Ib Study of HS-10504 Combined Therapy in NSCLC (NCT07414953) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-03-30 |
| Efficacy and Safety Study of HS-10542 for IgA Nephropathy (NCT07474636) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-03-17 |
| Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT07470762) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-02-14 |
| A Phase 3 Study of HS-20094 in Patients With T2DM (NCT07156539) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-09-30 |
| A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone (NCT07156500) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-09-30 |
| A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) (NCT06461156) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-07-22 |
| Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma (NCT07097935) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-07-10 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects (NCT07001787) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-06-01 |
| A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (NCT06963502) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-30 |
| Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 (NCT07033234) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-16 |
| HS-10542 Study in Healthy Participants (NCT07040046) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-16 |
| A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors (NCT06963398) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-15 |
| HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (NCT06769425) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-07 |
| Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 (NCT06846710) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-02 |
| A Study of HS-20094 in Overweight or Obese Participants (NCT07057674) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-04-16 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. (NCT06864507) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-03-31 |
| Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function (NCT06823258) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-02-28 |
| Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function (NCT06823245) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-02-28 |
| A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC (NCT06926413) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-02-20 |
| A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer (NCT07130916) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-12-05 |
| A Study of HS-20094 in Chinese Adults With Overweight or Obesity (NCT06839664) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-11-16 |
| A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors (NCT06594874) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-10-31 |
| A Study Evaluating Food Effect on Pharmacokinetics of HS-10518 (NCT06554548) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-08-15 |
| Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee Osteoarthritis (NCT07047196) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-08-13 |
| Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) (NCT06530810) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-07-31 |
| A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors (NCT06553339) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-07-19 |
| Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction (NCT06383897) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-05-31 |
| A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia (NCT07550387) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-05-23 |
| Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder (NCT06279286) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-05-01 |
| A Study of HS-10501 Tablets in Healthy Subjects (NCT06359600) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-03-14 |
| A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC) (NCT06246565) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-03-01 |
| The Phase I Study of HS-10509 in Chinese Adult Subjects (NCT06301074) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-03-01 |
| A Study of HS-20094 in Patients With T2DM (NCT06901648) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-02-06 |
| A Trial of HS-10511 in Healthy Subjects (NCT06210607) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-01-31 |
| A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy (NCT06110663) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-12-30 |
| A Study of HS-10518 in Healthy Female Participants (NCT06118827) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-11-01 |
| A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects (NCT06118021) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-10-16 |
| A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT06049030) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-09-25 |
| A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NCT06147570) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-09-25 |
| A Study of HS-10353 in Adult Participants With Major Depressive Disorder (NCT05938179) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-08-31 |
| A Phase II Study of HS-10353 in Participants With Postpartum Depression (NCT05937867) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-08-31 |
| Phase 1a Study in Healthy Participants (NCT05953506) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-07-17 |
| A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383 (NCT06092983) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-06-14 |
| A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (NCT05740956) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-06-09 |
| A Study of HS-20094 in T2DM Participants (NCT06118008) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-05-31 |
| Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults (NCT05777109) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-04-20 |
| A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors (NCT05911464) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-03-02 |
| Study of HS-10517 in Chinese Adult Participants (NCT05779579) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-02-01 |
| A Study of HS-10380 in Chinese Participants (NCT05480592) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-08-01 |
| A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors (NCT05378178) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-06-08 |
| Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors (NCT05367778) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-06-03 |
| A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (NCT05367765) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-04-30 |
| A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. (NCT05367700) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-04-28 |
| Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB (NCT06743438) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-03-10 |
| Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) (NCT05435248) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-03-02 |
| First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383 (NCT05429723) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-03-01 |
| A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer (NCT05504213) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-01-12 |
| Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC (NCT05430386) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-01-05 |
| A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. (NCT05353205) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-11-23 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects (NCT06033742) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-11-13 |
| Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors (NCT05207787) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-11-09 |
| A Study of HS-20094 in Healthy Participants (NCT05116410) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-11-01 |
| A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression (NCT05196971) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-10-28 |
| Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer (NCT05435274) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-09-30 |
| A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer (NCT05044988) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-09-30 |
| Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations (NCT04923906) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-08-11 |
| A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation (NCT04951648) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-07-15 |
| Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects. (NCT04986436) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-07-01 |
| Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations (NCT04687241) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-04-30 |
| A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (NCT04951635) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-03-18 |
| Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation (NCT04804267) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-03-05 |
| A Study of HS-10353 in Chinese Participants. (NCT05195203) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-01-27 |
| Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions (NCT04880993) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2020-12-14 |
| Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions (NCT04881006) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2020-12-10 |
| Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers (NCT04652297) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2020-12-01 |
| Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer (NCT04631835) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2020-09-08 |
| Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults (NCT04494373) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2020-09-01 |
| Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine (NCT04477096) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2020-08-03 |
| PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors (NCT04477057) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-06-21 |
| Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD (NCT03903809) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-06-20 |
| A Study of HS-10342 in Patients With Advanced Solid Tumor (NCT04060511) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-06-19 |
| Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis (NCT03902691) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-05-15 |